Biomark Diagnostics Full Year 2025 Earnings: CA$0.021 loss per share (vs CA$0.017 loss in FY 2024)

Biomark Diagnostics (FRA:20B) Full Year 2025 Results

Key Financial Results

• Net loss: CA$1.93m (loss widened by 35% from FY 2024).
• CA$0.021 loss per share (further deteriorated from CA$0.017 loss in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biomark Diagnostics shares are up 12% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Biomark Diagnostics (2 are significant!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.